Phase I study of recombinant human interferon beta in patients with advanced cancer.
Twenty-two patients with advanced cancer were entered into a phase I study of recombinant human interferon beta (IFN-beta). The maximum tolerated dose was 100 X 10(6) IU administered intravenously on a three times weekly schedule, and persistent fever was the dose-limiting toxicity. The majority of patients tolerated administration of IFN-beta well with negligible hematologic toxicity. Details of the clinical effects of escalating doses of recombinant human IFN-beta, administered three times weekly, are described.
D056486:Chemical and Drug Induced Liver Injury; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins